```
(FILE 'USPAT' ENTERED AT 11:22:22 ON 24 MAR 1998)
L1
          41151 S 424*?/CCLS
L2
          39784 S 435*?/CCLS
L3
          74747 S 514*?/CCLS
L4
         19855 S 530*?/CCLS
L5
           196 S SERTOLI (2A) CELL#
             1 S 5725854/PN
L6
L7
            41 S L1 AND L5
L8
           109 S L2 AND L5
L9
            42 S L3 AND L5
L10
           104 S L4 AND L5
           274 S DIABETES AND PANCREAT? (P) ISLET
L11
L12
             1 S L7 AND L11
L13
             0 S L8 AND L11
L14
             0 S L9 AND L11
L15
             0 S L10 AND L11
L16
            13 S L7 AND TRANSPLANT?
            28 S L8 AND TRANSPLANT?
L17
            10 S L9 AND TRANSPLANT?
L18
            16 S L10 AND TRANSPLANT?
L19
```

(FILE 'HOME' ENTERED AT 11:08:11 ON 24 MAR 1998)

	FILE	'HCAPI	บร	B, BIOSIS, MEDLINE' ENTERED AT 11:08:39 ON 24 MAR 1998	
L1		14803	s	SERTOLI (2A) CELL#	
L2		3	s	L1 AND DIABETES AND PANCREAT? (P) ISLET	
L3		12	s	L1 AND PANCREAT? (L) ISLET	
L4		190	s	SELAWRY, ?/AU	
L5		9	S	L4 AND SERTOLI	

ANSWER 1 OF 12 HCAPLUS COPYRIGHT 1998 ACS L3The present invention describes a method of treating a disease that AB results from a deficiency of a biol. factor which comprises administering to a mammal Sertoli cells and cells that produce the biol. factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunol. privilege site. A method of creating an immunol. privileged site and providing cell stimulatory factors in a mammal for transplants further described by the present invention. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product treating diabetes mellitus is further provided. The present invention further describes a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical compn. comprising Sertoli cells and cells that produce a biol. factor is also provided. 1997:127489 HCAPLUS ACCESSION NUMBER: 126:135688 DOCUMENT NUMBER: Use of co-localized islets and Sertoli TITLE: cells in xenograft cellular transplants INVENTOR(S): Selawry, Helena P. Research Corporation Technologies, Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 109 pp. SOURCE: CODEN: PIXXD2 NUMBER DATE _____ WO 9640178 A1 PATENT INFORMATION: 961219 DESIGNATED STATES: W: AU, CA, JP, MX, NO RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE APPLICATION INFORMATION: WO 96-US9627 960607 PRIORITY APPLN. INFO.: US 95-485340 950607 DOCUMENT TYPE: Patent LANGUAGE: English TI Use of co-localized islets and Sertoli cells in xenograft cellular transplants AB . . . method of treating a disease that results from a deficiency of a biol. factor which comprises administering to a mammal Sertoli cells and cells that produce the biol. factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunol. privilege site. A method of creating an immunol. privileged site and providing cell stimulatory factors in a mammal for transplants further described by the present invention. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product treating diabetes mellitus is further provided. The present invention further describes a method. . . enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical compn.

```
that produce a biol. factor is also provided.
     islet Sertoli cell xenograft cellular transplant
ST
IT
     Nucleic acids
     RL: BAC (Biological activity or effector, except adverse); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
        (biol. factors encoded by; in co-localized islets and
      Sertoli cells for xenograft cellular
        transplants)
    Antidiabetic agents
IT
     Drug delivery systems
     Islet transplant
     Sertoli cell
     Transplant (organ)
     Xenotransplant
        (use of co-localized islets and Sertoli cells
        in xenograft cellular transplants)
IΤ
     Diabetes mellitus
        (use of co-localized islets and Sertoli cells
        in xenograft cellular transplants for)
PΥ
     1996
     ANSWER 2 OF 12 HCAPLUS COPYRIGHT 1998 ACS
L3
AB
     Based on the detection of specific antibodies and T-cell
     sensitization in patients with IDDM, islet cell antigen
     p69 (ICAp69) has been suggested to be a target antigen of diabetic
     autoimmunity. The biol. function, tissue expression, and
     developmental kinetics of ICAp69 are largely unknown. We analyzed
     ICAp69 expression at the gene transcription and protein level in
     human and rodent tissues. By using template-calibrated quant.
     reverse transcriptase polymerase chain reaction (RT-PCR), high
     levels of ICAp69 mRNA were found in human pancreatic
     islets and brain. In mouse and rat, ICAp69 gene expression peaked
     in islet cell lines followed by testis, islets, and brain.
     ICAp69 mRNA was found at low levels in other organs by RT-PCR but
     not by Northern blot anal. In mice, ICAp69 transcription becomes
     detectable in fetal life, and fetal and adult gene expression
     patterns are similar. Western blot anal. of human and mouse tissues
     showed high expression of ICAp69 in brain, testis,
     pancreatic tissue, and islet cell lines. In these
     organs, ICAp69 immunoreactivity is predominately localized at the
     blood brain barrier (capillary endothelium), at the blood testis
     barrier (Sertoli cells and spermatids), and in
     pancreatic islets (.beta.-cells). The subcellular
     localization of ICAp69 to endoplasmic reticulum, Golgi complex, and
     vesicles by immune electron microscopy suggests a role of this
     neuroendocrine mol. in cellular protein in traffic and processing.
ACCESSION NUMBER:
                         1996:365083 HCAPLUS
DOCUMENT NUMBER:
                         125:82605
TITLE:
                         Gene expression of islet cell antigen p69 in
                         human, mouse, and rat
AUTHOR (S):
                         Karges, Wolfram; Pietropaolo, Massimo; Ackerley,
                         Cameron A.; Dosch, Hans-Michael
                         Dep. Pediatrics, Univ. Toronto, Toronto, ON,
CORPORATE SOURCE:
                         Can.
SOURCE:
                         Diabetes (1996), 45(4), 513-521
                         CODEN: DIAEAZ; ISSN: 0012-1797
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         English
     Based on the detection of specific antibodies and T-cell
     sensitization in patients with IDDM, islet cell antiqen
     p69 (ICAp69) has been suggested to be a target antigen of diabetic
     autoimmunity. The biol. function, tissue expression,.
     tissues. By using template-calibrated quant. reverse transcriptase
     polymerase chain reaction (RT-PCR), high levels of ICAp69 mRNA were
```

comprising Sertoli cells and cells

found in human pancreatic islets and brain. In mouse and rat, ICAp69 gene expression peaked in islet cell lines followed by testis, islets, and brain. ICAp69 mRNA was found at low levels in other organs by RT-PCR. . . expression patterns are similar. Western blot anal. of human and mouse tissues showed high expression of ICAp69 in brain, testis, pancreatic tissue, and islet cell lines. In these organs, ICAp69 immunoreactivity is predominately localized at the blood brain barrier (capillary endothelium), at the blood testis barrier (sertoli cells and spermatids), and in pancreatic islets (.beta.-cells). The subcellular localization of ICAp69 to endoplasmic reticulum, Golgi complex, and vesicles by immune electron microscopy suggests a. .

IT Animal tissue

Brain

Endoplasmic reticulum

Golgi apparatus

Pancreatic islet of Langerhans

Testis

(gene expression of **islet** cell antigen p69 in human, mouse, and rat)

PY 1996

AB

L3 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 1998 ACS

Peptide .alpha.-amidation, an essential posttranslational modification that confers bioactivity to many neuroendocrine peptides is catalyzed by peptidylglycine .alpha.-amidating monooxygenase (PAM; EC 1.14.17.3). To complement previous studies on the distribution of PAM in neuroendocrine organs, expression of the PAM gene in several endocrine tissues was examd. by in situ hybridization and immunocytochem. In all instances, the autoradiog. densities for PAM mRNA correlated with staining patterns for PAM immunoreactivity. Very high levels of PAM mRNA were found in all heart atrial cardiomyocytes, whereas much lower levels were present in ventricular cells. In the sublingual gland, PAM was expressed diffusely in both acinar and tubule cells. In contrast, expression of PAM was confined to granular convoluted tubule cells in the submaxillary gland. PAM was expressed at high levels in a subset of adrenal medullary chromaffin cells, and low levels of PAM mRNA and immunoreactivity were also detected in the adrenal cortex. PAM was found predominately in the calcitonin-producing parafollicular C-cells in the thyroid gland and in the glucagon-contg. A-cells in the endocrine pancreas. Collecting and distal tubule cells of the kidney expressed both PAM mRNA and immunoreactivity. The basal cells in testicular seminiferous tubules contq. PAM may represent developing germ and Sertoli cells. The cellular localization of PAM within the thyroid gland, adrenal gland, testis, and pancreas correlated with known peptidergic systems, and some of the obsd. cellular heterogeneity in PAM mRNA expression and immunoreactivity may reflect differences in the levels of amidated peptide prodn. The expression of PAM in cells not known to produce high levels of .alpha.-amidated peptides may indicate the prodn. of yet unidentified .alpha.-amidated bioactive peptides or alternative functions of the PAM protein.

ACCESSION NUMBER:

1992:463676 HCAPLUS

DOCUMENT NUMBER:

117:63676

TITLE:

Expression of peptidylglycine .alpha.-amidating monooxygenase: an in situ hybridization and

immunocytochemical study

AUTHOR (S):

Braas, Karen M.; Harakall, Susan A.; Ouafik, L'houchine; Eipper, Betty A.; May, Victor

CORPORATE SOURCE:

Coll. Med., Univ. Vermon, Burlington, VT, 05405,

USA

SOURCE:

Endocrinology (Baltimore) (1992), 130(5),

2778-88

CODEN: ENDOAO; ISSN: 0013-7227

DOCUMENT TYPE: Journal English LANGUAGE:

expressed both PAM mRNA and immunoreactivity. The basal cells in testicular seminiferous tubules contg. PAM may represent

developing germ and Sertoli cells. The cellular

localization of PAM within the thyroid gland, adrenal gland, testis, and pancreas correlated with known peptidergic systems, and.

Pancreatic islet of Langerhans ΙT

Salivary gland

Adrenal gland, composition

Heart, composition Kidney, composition Testis, composition

Thyroid gland, composition

(peptidylglycine amidating monooxygenase distribution in)

PΥ

AUTHOR (S):

ANSWER 4 OF 12 HCAPLUS COPYRIGHT 1998 ACS L3

Distribution of S-100 protein in the chick non-nervous tissues was AB investigated by an immunohistochem. method using anti-bovine S-100 protein serum. S-100 protein immunoreactivity was detected in stellate cells of the pituitary gland, insulin cells and somatostatin cells of the pancreatic islet, epithelial cells of the proventriculus, and epithelial cells of the distal and the collecting tubules in the kidney. The Sertoli cells and oocytes also contained S-100 protein. Evidently, occurrence and distribution of S-100 protein immunoreactivity cells of the chick is less numerous than that of mammals.

1991:182411 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 114:182411

TITLE: Immunohistochemical demonstration of S-100

protein in the chick non-nervous tissues Atoji, Yasuro; Takayanagi, Kouji; Suzuki,

Yoshitaka; Sugimura, Makoto

Fac. Agric., Gifu Univ., Gifu, 501-11, Japan CORPORATE SOURCE:

Zool. Sci. (1990), 7(4), 747-53 SOURCE: CODEN: ZOSCEX; ISSN: 0289-0003

DOCUMENT TYPE: Journal LANGUAGE: English

serum. S-100 protein immunoreactivity was detected in AB stellate cells of the pituitary gland, insulin cells and

somatostatin cells of the pancreatic islet,

epithelial cells of the proventriculus, and epithelial cells of the distal and the collecting tubules in the kidney. The

Sertoli cells and oocytes also contained S-100

protein. Evidently, occurrence and distribution of S-100 protein immunoreactivity cells of the chick is less. .

ΙT Testis, composition

> (Sertoli cell, protein S-100 localization in, of chicken)

Pancreatic islet of Langerhans ΙT

(.beta.-cell, protein S-100 of, of chicken)

ΙT Pancreatic islet of Langerhans

(.delta.-cell, protein S-100 of, of chicken)

PΥ 1990

ANSWER 5 OF 12 HCAPLUS COPYRIGHT 1998 ACS L3

The histogenesis of Ewing's sarcoma (ES), the second most frequent AΒ primary bone tumor in humans, remains controversial. A new cell line (SIM-1) was derived from a peripheral neuroectodermal tumor (PNET) and used for the prodn. of a monoclonal antibody (HBA-71), which recognizes a novel cell surface antigen of ES- and PNET-derived cells and paraffin-embedded tumor sections. The HBA-71 antigen expression is restricted to PNET/ES and the antigen was not detected on cell lines or tissue sections of any other tumor tested, with the exception of ependymoma. Three proteins with mol. wts. of 300,000, 185,000, and 90,000 were isolated from SIM-1 membrane exts. by HBA-71 affinity chromatog. Trypsin treatment of intact SIM-1 cells destroys the HBA-71 epitope and cleaves off two proteins with mol. wts. of 210,000 and 95,000. Within normal tissues reactivity was obsd. with the adenohypophysis, ependymal cells, endocrine pancreas, Sertoli, and ovary granulosa cells. The reagent links ES with PNET and provides a highly valuable probe for (a) the immunohistol. differential diagnosis of ES/PNET using fresh tissue or paraffin sections from other small round cell tumors, (b) the histogenetic studies of ES/PNET, and (c) in vivo diagnostic and therapeutic procedures in patients with ES and PNET.

ACCESSION NUMBER: 1988:628145 HCAPLUS

DOCUMENT NUMBER: 109:228145

TITLE: Characterization of a human endocrine tissue and

tumor-associated Ewing's sarcoma antigen

AUTHOR(S): Hamilton, Gerhard; Fellinger, Erich J.;

Schratter, Inge; Fritsch, Arnulf

CORPORATE SOURCE: Sch. Med., Univ. Vienna, Vienna, A-1090, Austria

SOURCE: Cancer Res. (1988), 48(21), 6127-31

CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal LANGUAGE: English

AB . . . off two proteins with mol. wts. of 210,000 and 95,000. Within normal tissues reactivity was obsd. with the adenohypophysis, ependymal cells, endocrine pancreas, Sertoli,

and ovary granulosa cells. The reagent links ES with PNET and provides a highly valuable probe for (a) the immunohistol.. .

IT Endocrine system

Pancreatic islet of Langerhans Pituitary gland, anterior lobe

(antigen HBA-71 of human, properties of)

IT Testis, composition

(Sertoli cell, antigen HBA-71 of human, properties of)

PY 1988

L3 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 1998 ACS

A polyclonal antiserum to bovine intestinal phosphodiesterase I (PDE AB I) was produced, and cross-reactivity was demonstrated with the human intestinal enzyme. This polyclonal antiserum was used in peroxidase-antiperoxidase immunocytochem. to localize immunoreactive PDE I in a variety of human tissues. Localization was prominent in the gastrointestinal tract, including the cytoplasm of gastric mucosa parietal cells, cytoplasm of surface epithelium and isolated crypt cells in small intestine, and the colonic epithelial cytoplasm and brush border. Parotid gland acinar cells and scattered ductal cells showed pos. cytoplasmic staining. Acinar and scattered pancreatic islet cells contained immunoreactive PDE I, as did Kupffer cells of the liver sinusoids. Immunoreactive PDE I was found in all vascular endothelia. The epithelium of the urinary tract showed extensive immunoreactivity. This included the distal convoluted and collecting tubules of the kidney and the ureteral and bladder urothelium. Immunoreactive PDE I was localized to human Sertoli cells and to basal epithelium of the epididymis and prostate acini. Fallopian tube epithelium of the female reproductive tract also demonstrated immunoreactive PDI I, as did several cell types in the term placenta. These immunocytochem. results with human tissues differ significantly from previous histochem. studies in animal tissues, principally in the genitourinary system. This may be due in part to the different detection systems employed as well as the higher sensitivity of the immunoperoxidase technique. This underscores the importance of

adjunct techniques in tissue surveys. The widespread epithelial distribution of immunoreactive PDE I detected by this polyclonal antibody implies an integral role in cell function, probably in active transport. 1987:64717 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 106:64717 Distribution of phosphodiesterase I in normal TITLE: human tissues Morley, Debra J.; Hawley, Dennis M.; Ulbright, AUTHOR (S): Thomas M.; Butler, Larry G.; Culp, Jeffrey S.; Hodes, M. E. Dep. Med. Genet., Indiana Univ. Med., CORPORATE SOURCE: Indianapolis, IN, USA J. Histochem. Cytochem. (1987), 35(1), 75-82 SOURCE: CODEN: JHCYAS; ISSN: 0022-1554 DOCUMENT TYPE: Journal LANGUAGE: English epithelial cytoplasm and brush border. Parotid gland acinar cells and scattered ductal cells showed pos. cytoplasmic staining. Acinar and scattered pancreatic islet cells contained immunoreactive PDE I, as did Kupffer cells of the liver sinusoids. Immunoreactive PDE I was found in all. convoluted and collecting tubules of the kidney and the ureteral and bladder urothelium. Immunoreactive PDE I was localized to human Sertoli cells and to basal epithelium of the epididymis and prostate acini. Fallopian tube epithelium of the female reproductive tract also demonstrated. . Epididymis Pancreatic islet of Langerhans Placenta Prostate gland (phosphodiesterase I of, of human) Testis, composition (Sertoli cell, phosphodiesterase I of, of human) 1987 ANSWER 7 OF 12 BIOSIS COPYRIGHT 1998 BIOSIS 96:505491 BIOSIS AB A lack of a sufficient number of human donor pancreases has stimulated interest in isolation and cryopreservation techniques for islets from the porcine pancreas. But because of a poorly developed outer membrane porcine islets are particularly susceptible to damage during cryopreservation. The aims of this study were twofold: 1) to develop a method for isolation and storage of islets from neonatal porcine pancreas and, 2) to examine effects of Sertoli cells on islet yield and function in Sertoli cell-islet cell cocultures. A total of 170 neonatal porcine pancreases were processed by means of a short period of digestion with collagenase and culture of the tissues at 32 degree C for periods up to 7 days following isolation. Results were: The mean +-SEM, number of viable islets, and percentage loss of cells following 7 days of culture were 29,442 +- 1,119 and 22.2 +- 1.2, respectively. Cryopreservation had a marked impact on recovery of viable islets: In absence of Sertoli cells an average of only 64% of islets remained viable; by contrast, when cryopreserved islets were cocultured with Sertoli cells, a mean of 82% was recovered. Glucose at 16.7 mmol/L had the capacity to elicit insulin release from 3-day-old cultured islets. The concentration in absence of Sertoli cells was 57.3 +- 3.8, uU/mL/10 islets; in the presence of

Sertoli cells the level increased to a mean +- SEM

of 112.8 t 17.7, uU/mL/10 islets. Similar results were obtained following cryopreservation: glucose at 16.7 mmol/L stimulated a mean +- SEM of 27.9 +- 6.6, uU/mL/10 islets, of insulin in absence of, and

IT

IT

PY

44.9 +- 9.9, uU/mL/10 islets, in presence of, Sertoli cells. Our results show that isolation and cryopreservation of neonatal porcine islets can be successfully accomplished. In addition, coculture with Sertoli cells significantly improves both the yield and functional capacity of islets following cryopreservation. DOCUMENT NUMBER: 99227847 Sertoli cell-induced effects TITLE: on functional and structural characteristics of isolated neonatal porcine islets. Selawry H P; Wang X; Alloush L AUTHOR (S): Veterans Affairs Med. Cent., Research 151, 1030 CORPORATE SOURCE: Jefferson Ave., Memphis, TN 38104, USA Cell Transplantation 5 (5). 1996. 517-524. ISSN: SOURCE: 0963-6897 English LANGUAGE: TI Sertoli cell-induced effects on functional and structural characteristics of isolated neonatal porcine islets. . to develop a method for isolation and storage of islets from neonatal porcine pancreas and, 2) to examine effects of Sertoli cells on islet yield and function in Sertoli cell-islet cell cocultures. A total of 170 neonatal porcine pancreases were processed by means of a short period of digestion with collagenase. . . +- 1,119 and 22.2 +- 1.2, respectively. Cryopreservation had a marked impact on recovery of viable islets: In absence of Sertoli cells an average of only 64% of islets remained viable; by contrast, when cryopreserved islets were cocultured with Sertoli cells, a mean of 82% was recovered. Glucose at 16.7 mmol/L had the capacity to elicit insulin release from 3-day-old cultured islets. The concentration in absence of Sertoli cells was 57.3 +- 3.8, uU/mL/10 islets; in the presence of Sertoli cells the level increased to a mean +- SEM of 112.8 t 17.7, uU/mL/10 islets. Similar results were obtained following cryopreservation: . . of 27.9 +- 6.6, uU/mL/10 islets, of insulin in absence of, and 44.9 +- 9.9, uU/mL/10 islets, in presence of, Sertoli cells. Our results show that isolation and cryopreservation of neonatal porcine islets can be successfully accomplished. In addition, coculture with Sertoli cells significantly improves both the yield and functional capacity of islets following cryopreservation. RESEARCH ARTICLE; PORCINE; NEONATE; SERTOLI CELL; PANCREATIC ISLET CELL; CRYOPRESERVATION; CELL BIOLOGY; METHODOLOGY; MISCELLANEOUS METHOD ANSWER 8 OF 12 BIOSIS COPYRIGHT 1998 BIOSIS L3 AN 96:218340 BIOSIS AB Based on the detection of specific antibodies and T-cell sensitization in patients with EDDM, islet cell antigen p69 (ICAp69) has been suggested to be a target antigen of diabetic autoimmunity. The biological function, tissue expression, and developmental kinetics of ICAp69 are largely unknown. We analyzed ICAp69 expression at the gene transcription and protein level in human and rodent tissues. By using template-calibrated quantitative reverse transcriptase polymerase chain reaction (RT-PCR), high levels of ICAp69 mRNA were found in human pancreatic islets and brain. In mouse and rat, ICAp69 gene expression peaked in islet cell lines followed by testis, islets, and brain. ICAp69 mRNA was found at low levels in other organs by RT-PCR but not by Northern blot analysis. In mice, ICAp69 transcription becomes detectable in fetal life, and fetal and adult gene expression patterns are similar. Western blot analysis of human and mouse

tissues showed high expression of ICAp69 in brain, testis,

organs, ICAp69 immunoreactivity is predominately localized at the

pancreatic tissue, and islet cell lines. In these

blood brain barrier (capillary endothelium), at the blood testis barrier (Sertoli cells and spermatids), and in

pancreatic islets (beta-cells). The subcellular localization of ICAp69 to endoplasmic reticulum, Golgi complex, and vesicles by immune electron microscopy suggests a role of this neuroendocrine molecule in cellular protein traffic and processing.

DOCUMENT NUMBER: 98774469

TITLE: Gene expression of islet cell antigen p69 in

human, mouse, and rat.

AUTHOR(S): Karges W; Pietropaolo M; Ackerley C A; Dosch H-M CORPORATE SOURCE: Dep. Pediatrics Immunology, Hosp. Sick Children,

555 University Ave., Toronto, ON M5G 1X8, Canada

SOURCE: Diabetes 45 (4). 1996. 513-521. ISSN: 0012-1797

LANGUAGE: English

AB Based on the detection of specific antibodies and T-cell sensitization in patients with EDDM, islet cell antigen p69 (ICAp69) has been suggested to be a target antigen of diabetic autoimmunity. The biological function, tissue expression, . . . tissues. By using template-calibrated quantitative reverse transcriptase polymerase chain reaction (RT-PCR), high levels of ICAp69 mRNA were found in human pancreatic islets and brain. In mouse and rat, ICAp69 gene expression peaked in

islet cell lines followed by testis, islets, and brain.
 ICAp69 mRNA was found at low levels in other organs by RT-PCR. .
 expression patterns are similar. Western blot analysis of human and
 mouse tissues showed high expression of ICAp69 in brain, testis,

pancreatic tissue, and islet cell lines. In these
 organs, ICAp69 immunoreactivity is predominately localized at the
 blood brain barrier (capillary endothelium), at the blood testis
 barrier (Sertoli cells and spermatids), and in

pancreatic islets (beta-cells). The subcellular localization
 of ICAp69 to endoplasmic reticulum, Golgi complex, and vesicles by
 immune electron microscopy suggests a. . .

L3 ANSWER 9 OF 12 BIOSIS COPYRIGHT 1998 BIOSIS

AN 90:517941 BIOSIS

AB Distribution of S-100 protein in the chick non-nervous tissues was investigated by immunohistochemical method using anti-bovine S-100 protein serum. S-100 protein immunoreactivity was detected in stellate cells of the pituitary gland, insulin cells and somatostatin cells of the pancreatic islet, epithelial cells of the distal and the collecting tubules in the kidney. The Sertoli cells and oocytes also contained S-100 protein. These findings indicate that the occurrence and distribution of S-100 protein immunoreactive cells of the chick is less numerous than that of mammals.

DOCUMENT NUMBER: BA90:135217

TITLE: IMMUNOHISTOCHEMICAL DEMONSTRATION OF S-100 PROTEIN

IN THE CHICK NON-NERVOUS TISSUES.

AUTHOR(S): ATOJI Y; TAKAYANAGI K; SUZUKI Y; SUGIMURA M

CORPORATE SOURCE: DEP. VET. ANATOMY, FAC. AGRIC., GIFU UNIV., GIFU

501-11.

SOURCE: ZOOL SCI (TOKYO) 7 (4). 1990. 747-754. CODEN:

ZOSCEX ISSN: 0289-0003

LANGUAGE: English

AB . . . serum. S-100 protein immunoreactivity was detected in stellate cells of the pituitary gland, insulin cells and somatostatin cells of the pancreatic islet, epithelial cells of the proventriculus, and epithelial cells of the distal and the collecting tubules in the kidney. The Sertoli cells and oocytes also contained S-100 protein. These findings indicate that the occurrence and distribution of S-100 protein immunoreactive cells of. . .

ST PITUITARY STELLATE CELL PANCREATIC INSULIN CELL SOMATOSTATIN CELL PROVENTRICULAR EPITHELIAL CELL KIDNEY EPITHELIUM

```
ANSWER 10 OF 12 BIOSIS COPYRIGHT 1998 BIOSIS
T.3
AN 87:129856 BIOSIS
AB Phosphodiesterase I (PDE I) is an exonuclease capable of hydrolyzing
    a variety of phosphate ester and pyrophosphate bonds. Cell
    fractionation and histochemical studies in animal tissues have
    localized PDE I in the plasma membrane of various epithelia. This
    suggests a role for the enzyme in active transport. Distribution of
    PDE I in human tissues has not previously been studied. We have
    produced a polyclonal antiserum to bovine intestinal PDE I and have
    demonstrated crossreactivity with the human intestinal enzyme. This
    polyclonal antiserum was used in PAP immunocytochemistry to localize
    immunoreactive PDE I in a variety of human tissues. Localization was
    prominent in the gastrointestinal tract, including of the cytoplasma
    of gastric mucosa parietal cells, cytoplasm of surface epithelium and
    isolated crypt cells in small intestine, and the colonic epithelial
    cytoplasm and brush border. Parotid gland acinar cells and scattered
    ductal cells showed positive cytoplasmic staining. Acinar and
    scattered pancreatic islet cells contained
    immunoreactive PDE I, as did Kuppfer cells of the liver sinusoids.
    Immunoreactive PDE I was found in all vascular endothelial. The
    epithelium of the urinary tract showed extensive immunoreactivity.
    This included the distal convoluted and collecting tubules of the
    kidney, and ureteral and bladder urothelium. In previous
    histochemical studies of animal tissues, no evidence of PDE I
    activity was noted in male or female reproductive tract. In this
    study, immunoreactive PDE I was localized to human Sertoli
  cells and to basal epithelium of the epididymis and prostate
    acini. Fallopian tube epithelium of female reproductive tract also
    demonstrated immunoreactive PDI I, as did several cell types in term
    placenta. Our immunocytochemical results with human tissues differ
    significantly from previous histochemical studies in animal tissues,
    principally in the genitourinary system. This may be due in part to
    the different detection systems employed as well as the higher
    sensitivity of the immunoperoxidase technique. This underscores the
    importance of adjunct techniques in tissue surveys. The widespread
    epithelial distribution of immunoreactive PDE I detected by this
    polyclonal antibody implies an integral role in cell function,
    probably in active transport.
DOCUMENT NUMBER:
                       BA83:68917
TITLE:
                       DISTRIBUTION OF PHOSPHODIESTERASE I IN NORMAL
                       HUMAN TISSUES.
AUTHOR (S):
                       MORLEY D J; HAWLEY D M; ULBRIGHT T M; BUTLER L G;
                       CULP J S; HODES M E
CORPORATE SOURCE:
                       DEP. OF MED. GENETICS, INDIANA UNIV. SCH. OF MED.,
                       702 BARNHILL DR., INDIANAPOLIS, INDIANA 46223.
SOURCE:
                       J HISTOCHEM CYTOCHEM 35 (1). 1987. 75-82. CODEN:
                       JHCYAS ISSN: 0022-1554
LANGUAGE:
                       English
   . . . epithelial cytoplasm and brush border. Parotid gland acinar
    cells and scattered ductal cells showed positive cytoplasmic
    staining. Acinar and scattered pancreatic islet
    cells contained immunoreactive PDE I, as did Kuppfer cells of the
    liver sinusoids. Immunoreactive PDE I was found in all.
    activity was noted in male or female reproductive tract. In this
    study, immunoreactive PDE I was localized to human Sertoli
  cells and to basal epithelium of the epididymis and prostate
    acini. Fallopian tube epithelium of female reproductive tract also
    demonstrated immunoreactive.
   COW IMMUNOPEROXIDASE TECHNIQUE ANIMAL TISSUES SERTOLI
  CELLS KIDNEY BLOOD VESSELS KUPFFER CELLS PANCREATIC
  ISLET CELLS PAROTID GLAND ACINAR CELLS INTESTINE
    IMMUNOCYTOCHEMISTRY CROSS-REACTIVITY ACTIVE TRANSPORT EPITHELIAL
```

PLASMA MEMBRANE HISTOCHEMISTRY CELL FRACTIONATION

L3 ANSWER 11 OF 12 MEDLINE

Based on the detection of specific antibodies and T-cell AB sensitization in patients with IDDM, islet cell antigen p69 (ICAp69) has been suggested to be a target antigen of diabetic autoimmunity. The biological function, tissue expression, and developmental kinetics of ICAp69 are largely unknown. We analyzed ICAp69 expression at the gene transcription and protein level in human and rodent tissues. By using template-calibrated quantitative reverse transcriptase polymerase chain reaction (RT-PCR), high levels of ICAp69 mRNA were found in human pancreatic islets and brain. In mouse and rat, ICAp69 gene expression peaked in islet cell lines followed by testis, islets, and brain. ICAp69 mRNA was found at low levels in other organs by RT-PCR but not by Northern blot analysis. In mice, ICAp69 transcription becomes detectable in fetal life, and fetal and adult gene expression patterns are similar. Western blot analysis of human and mouse tissues showed high expression of ICAp69 in brain, testis, pancreatic tissue, and islet cell lines. In these organs, ICAp69 immunoreactivity is predominately localized at the blood brain barrier (capillary endothelium), at the blood testis barrier (Sertoli cells and spermatids), and in pancreatic islets (beta-cells). The subcellular localization of ICAp69 to endoplasmic reticulum, Golgi complex, and vesicles by immune electron microscopy suggests a role of this neuroendocrine molecule in cellular protein traffic and processing.off

ACCESSION NUMBER: 96177282 MEDLINE

DOCUMENT NUMBER: 96177282

TITLE: Gene expression of islet cell antigen p69 in human,

mouse, and rat.

AUTHOR: Karges W; Pietropaolo M; Ackerley C A; Dosch H M

CORPORATE SOURCE: Department of Pediatrics and Immunology, University

of Toronto, Ontario, Canada.

SOURCE: DIABETES, (1996 Apr) 45 (4) 513-21.

Journal code: E8X. ISSN: 0012-1797.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 199607

Based on the detection of specific antibodies and T-cell sensitization in patients with IDDM, islet cell antigen p69 (ICAp69) has been suggested to be a target antigen of diabetic autoimmunity. The biological function, tissue expression,. tissues. By using template-calibrated quantitative reverse transcriptase polymerase chain reaction (RT-PCR), high levels of ICAp69 mRNA were found in human pancreatic islets and brain. In mouse and rat, ICAp69 gene expression peaked in islet cell lines followed by testis, islets, and brain. ICAp69 mRNA was found at low levels in other organs by RT-PCR. expression patterns are similar. Western blot analysis of human and mouse tissues showed high expression of ICAp69 in brain, testis, pancreatic tissue, and islet cell lines. In these organs, ICAp69 immunoreactivity is predominately localized at the blood brain barrier (capillary endothelium), at the blood testis barrier (Sertoli cells and spermatids), and in pancreatic islets (beta-cells). The subcellular localization of ICAp69 to endoplasmic reticulum, Golgi complex, and vesicles by immune electron microscopy suggests a. PΥ

L3 ANSWER 12 OF 12 MEDLINE

AB Phosphodiesterase I (PDE I) is an exonuclease capable of hydrolyzing a variety of phosphate ester and pyrophosphate bonds. Cell fractionation and histochemical studies in animal tissues have

suggests a role for the enzyme in active transport. Distribution of PDE I in human tissues has not previously been studied. We have produced a polyclonal antiserum to bovine intestinal PDE I and have demonstrated crossreactivity with the human intestinal enzyme. This polyclonal antiserum was used in PAP immunocytochemistry to localize immunoreactive PDE I in a variety of human tissues. Localization was prominent in the gastrointestinal tract, including the cytoplasm of gastric mucosa parietal cells, cytoplasm of surface epithelium and isolated crypt cells in small intestine, and the colonic epithelial cytoplasm and brush border. Parotid gland acinar cells and scattered ductal cells showed positive cytoplasmic staining. Acinar and scattered pancreatic islet cells contained immunoreactive PDE I, as did Kupffer cells of the liver sinusoids. Immunoreactive PDE I was found in all vascular endothelia. The epithelium of the urinary tract showed extensive immunoreactivity. This included the distal convoluted and collecting tubules of the kidney, and ureteral and bladder urothelium. In previous histochemical studies of animal tissues, no evidence of PDE I activity was noted in male or female reproductive tract. In this study, immunoreactive PDE I was localized to human Sertoli cells and to basal epithelium of the epididymis and prostate acini. Fallopian tube epithelium of female reproductive tract also demonstrated immunoreactive PDI I, as did several cell types in term placenta. Our immunocytochemical results with human tissues differ significantly from previous histochemical studies in animal tissues, principally in the genitourinary system. This may be due in part to the different detection systems employed as well as the higher sensitivity of the immunoperoxidase technique. This underscores the importance of adjunct techniques in tissue surveys. The widespread epithelial distribution of immunoreactive PDE I detected by this polyclonal antibody implies an integral role in cell function, probably in active transport.

localized PDE I in the plasma membrane of various epithelia. This

ACCESSION NUMBER: 87084682 MEDLINE

DOCUMENT NUMBER: 87084682

TITLE: Distribution of phosphodiesterase I in normal human

tissues.

AUTHOR: Morley D J; Hawley D M; Ulbright T M; Butler L G;

Culp J S; Hodes M E

SOURCE: JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, (1987

Jan) 35 (1) 75-82.

Journal code: IDZ. ISSN: 0022-1554.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals; Cancer Journals

ENTRY MONTH: 198704

AB . . . epithelial cytoplasm and brush border. Parotid gland acinar cells and scattered ductal cells showed positive cytoplasmic staining. Acinar and scattered pancreatic islet cells contained immunoreactive PDE I, as did Kupffer cells of the liver sinusoids. Immunoreactive PDE I was found in all. . . I activity was noted in male or female reproductive tract. In this study, immunoreactive PDE I was localized to human Sertoli cells and to basal epithelium of the epididymis and prostate acini. Fallopian tube epithelium of female reproductive tract also demonstrated immunoreactive. . .

PY 1987

=> s selawry, ?/au

L4 190 SELAWRY, ?/AU

=> s 14 and sertoli

=> d 15 abs ibib py 1-9

L5 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 1998 ACS

The present invention describes a method of treating a disease that AB results from a deficiency of a biol. factor which comprises administering to a mammal Sertoli cells and cells that produce the biol. factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunol. privilege site. A method of creating an immunol. privileged site and providing cell stimulatory factors in a mammal for transplants further described by the present invention. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product treating diabetes mellitus is further provided. The present invention further describes a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical compn. comprising Sertoli cells and cells that produce a biol. factor is also provided.

ACCESSION NUMBER: 1997:127489 HCAPLUS

DOCUMENT NUMBER: 126:135688

TITLE: Use of co-localized islets and Sertoli

cells in xenograft cellular transplants

INVENTOR(S): Selawry, Helena P.

PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

NUMBER DATE
----WO 9640178 A1 961219

DESIGNATED STATES: W: AU, CA, JP, MX, NO

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE,

IT, LU, MC, NL, PT, SE

APPLICATION INFORMATION: WO 96-US9627 960607 PRIORITY APPLN. INFO.: US 95-485340 950607

DOCUMENT TYPE: Patent LANGUAGE: English

PY 1996

PATENT INFORMATION:

L5 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 1998 ACS

The testis is a remarkable immune-privileged site, long known for AB its ability to support allogeneic and xenogeneic tissue transplants. Here we have investigated the mol. basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Apo-1) ligand survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligand, were rejected. Further anal. of testis showed that CD95 ligand mRNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.

ACCESSION NUMBER: 1995:885546 HCAPLUS

DOCUMENT NUMBER: 123:283572

TITLE: A role for CD95 ligand in preventing graft

rejection

AUTHOR(S): Bellgrau, Donald; Gold, Daniel; Selawry,

Helena; Moore, Jordene; Franzusoff, Alex;

Duke, Richard C.

CORPORATE SOURCE: Sch. Med., Univ. Colorado, Denver, CO, 80262,

USA

SOURCE: Nature (London) (1995), 377(6550), 630-2

CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: LANGUAGE: Journal English

PY 1995

L5 ANSWER 3 OF 9 BIOSIS COPYRIGHT 1998 BIOSIS

AN 96:505491 BIOSIS

AB A lack of a sufficient number of human donor pancreases has stimulated interest in isolation and cryopreservation techniques for islets from the porcine pancreas. But because of a poorly developed outer membrane porcine islets are particularly susceptible to damage during cryopreservation. The aims of this study were twofold: 1) to develop a method for isolation and storage of islets from neonatal porcine pancreas and, 2) to examine effects of **Sertoli** cells on islet yield and function in **Sertoli** cell-islet cell cocultures. A total of 170 neonatal porcine pancreases were processed by means of a short period of digestion with collagenase and culture of the tissues at 32 degree C for periods up to 7 days following isolation. Results were: The mean +-SEM, number of viable islets, and percentage loss of cells following 7 days of culture were 29,442 +- 1,119 and 22.2 +- 1.2, respectively. Cryopreservation had a marked impact on recovery of viable islets: In absence of

Sertoli cells an average of only 64% of islets remained
 viable; by contrast, when cryopreserved islets were cocultured with
Sertoli cells, a mean of 82% was recovered. Glucose at 16.7
 mmol/L had the capacity to elicit insulin release from 3-day-old
 cultured islets. The concentration in absence of Sertoli

cells was 57.3 +- 3.8, uU/mL/10 islets; in the presence of **sertoli** cells the level increased to a mean +- SEM of 112.8 t 17.7, uU/mL/10 islets. Similar results were obtained following cryopreservation: glucose at 16.7 mmol/L stimulated a mean +- SEM of 27.9 +- 6.6, uU/mL/10 islets, of insulin in absence of, and 44.9 +- 9.9, uU/mL/10 islets, in presence of, **sertoli** cells. Our results show that isolation and cryopreservation of neonatal porcine islets can be successfully accomplished. In addition, coculture with

Sertoli cells significantly improves both the yield and functional capacity of islets following cryopreservation.

DOCUMENT NUMBER: 99227847

TITLE: Sertoli cell-induced effects on

functional and structural characteristics of

isolated neonatal porcine islets.

AUTHOR(S):

Selawry H P; Wang X; Alloush L

CORPORATE SOURCE:

Veterans Affairs Med. Cent., Research 151, 1030

Jefferson Ave., Memphis, TN 38104, USA

SOURCE:

Cell Transplantation 5 (5). 1996. 517-524. ISSN:

0963-6897

LANGUAGE: English

L5 ANSWER 4 OF 9 BIOSIS COPYRIGHT 1998 BIOSIS

AN 95:534201 BIOSIS

AB Testis is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants". Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Apo-1) ligand survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligand-8,9, were rejected. Further analysis of testis

showed that CD95 ligand messenger RNA is constitutively expressed by testicular **Sertoli** cells, and that **Sertoli** cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immuneprivileged tissue for a variety of transplant uses.

DOCUMENT NUMBER: 98548501

TITLE: A role for CD95 ligand in preventing graft

rejection.

AUTHOR(S): Bellgrau D; Gold D; Selawry H; Moore J;

Franzusoff A; Duke R C

CORPORATE SOURCE: Dep. Immunol., Univ. Colo. Sch. Med., Denver, CO

80262, USA

SOURCE: Nature (London) 377 (6550). 1995. 630-632. ISSN:

0028-0836

LANGUAGE: English

L5 ANSWER 5 OF 9 BIOSIS COPYRIGHT 1998 BIOSIS

AN 92:96787 BIOSIS

AB Isolated islet allografts survive indefinitely in the abdominal testis of nonimmunosuppressed diabetic rats. The predominant feature of these testes is that the presence of **Sertoli** cells, but not Leydig cells, is required for extended survival of the islet allografts. **Sertoli** cell cultures were therefore established in vitro and we examined the effects of the conditioned media on Con A-stimulated spleen lymphocyte proliferation. These studies revealed that a product(s) secreted by **Sertoli** cells inhibits Con A-stimulated lymphocyte proliferation in a dose-dependent manner. The synthesis of this product is both temperature-dependent, occurring predominantly at 37.degree. C, and hormone-dependent, requiring the presence of follicle stimulating hormone, in the culture medium. We further examined the mechanism of inhibition of lymphocyte proliferation and showed that

Sertoli cell-enriched media inhibit the production of IL-2 in a dose-dependent manner. Furthermore, the finding that the addition of exogenous IL-2 is not able to reverse this inhibition indicates that the Sertoli cell-enriched media inhibit both IL-2 production and IL-2 responsiveness of T lymphocytes.

DOCUMENT NUMBER: BA93:53337

TITLE: PRODUCTION OF A FACTOR OR FACTORS SUPPRESSING IL-2

PRODUCTION AND T CELL PROLIFERATION BY

SERTOLI CELL-ENRICHED PREPARATIONS.

AUTHOR(S): SELAWRY H P; KOTB M; HERROD H G; LU Z-N

CORPORATE SOURCE: VAMC, RES. 151, 1030 JEFFERSON AVE., MEMPHIS,

TENN. 38104.

SOURCE: TRANSPLANTATION (BALTIMORE) 52 (5). 1991.

846-850. CODEN: TRPLAU ISSN: 0041-1337

LANGUAGE: English

L5 ANSWER 6 OF 9 MEDLINE

AB A lack of a sufficient number of human donor pancreases has stimulated interest in isolation and cryopreservation techniques for islets from the porcine pancreas. But because of a poorly developed outer membrane porcine islets are particularly susceptible to damage during cryopreservation. The aims of this study were two-fold: 1) to develop a method for isolation and storage of islets from neonatal porcine pancreas and, 2) to examine effects of **Sertoli** cells on islet yield and function in **Sertoli** cell-islet cell cocultures. A total of 170 neonatal porcine pancreases were processed by means of a short period of digestion with collagenase and culture of the tissues at 32 degrees C for periods up to 7 days following isolation. Results were: The mean +/- SEM, number of viable islets, and percentage loss of cells following 7 days of

culture were 29,442 +/- 1,119 and 22.2 +/- 1.2, respectively, Cryopreservation had a marked impact on recovery of viable islets: In absence of Sertoli cells an average of only 64% of islets remained viable; by contrast, when cryopreserved islets were cocultured with Sertoli cells, a mean of 82% was recovered. Glucose at 16.7 mmol/L had the capacity to elicit insulin release from 3-day-old cultured islets. The concentration in absence of Sertoli cells was 57.3 +/- 3.8 uU/mL/10 islets; in the presence of Sertoli cells the level increased to a mean +/- SEM of 112.8 +/- 17.7, uU/mL/10 islets. Similar results were obtained following cryopreservation: glucose at 16.7 mmol/L stimulated a mean +/- SEM of 27.9 +/- 6.6, uU/mL/10 islets, of insulin in absence of, and 44.9 \pm 9.9, uU/mL/10 islets, in presence of, Sertoli cells. Our results show that isolation and cryopreservation of neonatal porcine islets can be successfully accomplished. In addition, coculture with Sertoli cells significantly improves both the yield and functional capacity of islets following cryopreservation.

ACCESSION NUMBER: 97044140 MEDLINE

DOCUMENT NUMBER: 9

97044140

TITLE:

Sertoli cell-induced defects on functional

and structural characteristics of isolated neonatal

porcine islets.

AUTHOR: Selawry H P; Wang X; Alloush L

CORPORATE SOURCE: Department of Veterans Affairs Medical Center,

Memphis, TN 38104, USA.

CONTRACT NUMBER: DK-42421-05 (NIDDK)

SOURCE: CELL TRANSPLANTATION, (1996 Sep-Oct) 5 (5) 517-24.

Journal code: B02. ISSN: 0963-6897.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199704 ENTRY WEEK: 19970402

PY 1996

L5 ANSWER 7 OF 9 MEDLINE

Testis is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants. Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Apo-1) ligand survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligand, were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.

ACCESSION NUMBER: 96026301 MEDLINE

DOCUMENT NUMBER: 96026301

TITLE: A role for CD95 ligand in preventing graft rejection

[see comments].

COMMENT: Comment in: Nature 1995 Oct 19;377(6550):576

Comment in: Nature 1996 Feb 22;379(6567):682

AUTHOR: Bellgrau D; Gold D; Selawry H; Moore J;

Franzusoff A; Duke R C

CORPORATE SOURCE: Department of Immunology, University of Colorado

School of Medicine, Denver 80262, USA.

SOURCE: NATURE, (1995 Oct 19) 377 (6550) 630-2.

Journal code: NSC. ISSN: 0028-0836.

PUB. COUNTRY: ENGLAND: United Kingdom

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Cancer Journals; Priority Journals

ENTRY MONTH: 199601

PY 1995

L5 ANSWER 8 OF 9 MEDLINE

Prolonged survival of Islet- allo- and xenografts can be induced AB following implantation of the islets into the abdominal testis of diabetic rats. We previously showed that a factor released by Sertoli cells appears to be responsible for the protection of the intratesticular islet allo- and xenografts against rejection. The aim of this study was to examine whether an immunologically privileged site can be established in an organ site in vivo, other than the testis, such as the renal, subcapsular space, to make feasible the grafting of female recipients as well. A total of 36 male and 21 female, diabetic, PVG rats were divided into six different treatment groups: 1) Six male rats were grafted with islets from Spraque-Dawley (S-D) donor rats only. 2) Ten male rats were grafted with islets from (S-D) donors and were then given a short course of cyclosporine (CsA) posttransplantation. 3) Ten male rats were grafted with islets from (S-D) donors and with Sertoli cell-enriched fractions (SEF) from PVG donors but without CsA. 4) Ten male rats were grafted with a combination of islets from (S-D) and SEF from (PVG), donors, respectively, and CsA. 5) Ten female rats were given an identical combination of cells and CsA as depicted for group 5. 6) Ten female rats were grafted with a combination of islets and SEF, both cell types from S-D donors, and CsA. The results showed that 70% to 100% of the grafted rats in groups 1, 2, and 3 remained hyperglycemic. (ABSTRACT TRUNCATED AT 250 WORDS)

ACCESSION NUMBER: 94191899 MEDLINE

DOCUMENT NUMBER:

94191899

00

TITLE: Sertoli cell-enriched fractions in successful islet cell transplantation.

AUTHOR: Selawry H P; Cameron D F

CORPORATE SOURCE:

Department of Veterans Affairs Medical Center,

Memphis, TN 38104..

SOURCE:

CELL TRANSPLANTATION, (1993 Mar-Apr) 2 (2) 123-9.

Journal code: B02. ISSN: 0963-6897.

PUB. COUNTRY:

United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199407

PY 1993

L5 ANSWER 9 OF 9 MEDLINE

AB Isolated islet allografts survive indefinitely in the abdominal testis of nonimmunosuppressed diabetic rats. The predominant feature of these testes is that the presence of **Sertoli** cells, but not Leydig cells, is required for extended survival of the islet allografts. **Sertoli** cells cultures were therefore established in vitro and we examined the effects of the conditioned media on Con A--stimulated spleen lymphocyte proliferation. These studies revealed that a product(s) secreted by **Sertoli** cells inhibits Con A-stimulated lymphocyte proliferation in a dose-dependent manner. The synthesis of this product is both temperature-dependent, occurring predominantly at 37 degrees C, and hormone-dependent, requiring the presence of follicle stimulating hormone, in the culture medium. We further examined the mechanism of inhibition of lymphocyte proliferation and showed that **Sertoli** cell-enriched media inhibit the production of IL-2

in a dose-dependent manner. Furthermore, the finding that the addition of exogenous IL-2 is not able to reverse this inhibition

indicates that the Sertoli cell-enriched media inhibit

both IL-2 production and IL-2 responsiveness of T lymphocytes.

ACCESSION NUMBER: 92055960 MEDLINE

DOCUMENT NUMBER:

92055960

TITLE:

Production of a factor, or factors, suppressing IL-2

production and T cell proliferation by **Sertoli** cell-enriched preparations. A

potential role for islet transplantation in an

immunologically privileged site.

AUTHOR:

Selawry H P; Kotb M; Herrod H G; Lu Z N

CORPORATE SOURCE:

Veterans Administration Medical Center, Memphis,

Tennessee..

CONTRACT NUMBER:

RO1 DK40341-01A1 (NIDDK)

SOURCE:

TRANSPLANTATION, (1991 Nov) 52 (5) 846-50.

Journal code: WEJ. ISSN: 0041-1337.

PUB. COUNTRY:

United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals; Cancer Journals

ENTRY MONTH:

199202

PY 1991

=> d his